Single Source Procurement: Opioid Overdose Prevention Program

Pursuant to New York State Finance Law § 163.10(b), The New York State Department of Health is presenting the following summary of relevant circumstances, and material and substantial reasons why a competitive procurement was not feasible. The New York State Department of Health, Office of Public Health, AIDS Institute, has made a determination to extend its contract with Emergent Devices, Inc. (formerly Adapt Pharma, Inc.) for an additional 12 months at a cost not to exceed $7,500,000. Emergent Devices, Inc. is the sole manufacturer of Narcan®. This product was approved by the Food Drug Administration (FDA) on November 15, 2015 and has a patent (patent 9480644) until March 16, 2035. The Narcan® will be provided to opioid overdose prevention programs registered with the NYS DOH AIDS Institute. Emergent Devices, Inc. will fill orders approved by the AIDS Institute and ship the naloxone to the registered opioid overdose prevention programs. The additional funding is needed in response to the growing opioid overdose epidemic in New York State.

Procurement / Program Name Opioid Overdose Prevention Program
Contractor Name(s) Emergent Devices, Inc. (formerly Adapt Pharma, Inc.)
Contract Period 08/01/2021 to 7/31/2022
Contract Number(s) C033007